There has been a marked, unexplained increasing incidence of neuroendocrine tumors (NETs) over the past few decades. This may be due to a combination of different factors, such as changes in the environment with new exposures to injurious agents or an increased awareness of these neoplasms, but perhaps most of all, improvements in and utilization of body imaging. It has been estimated that as many as 72 million computed tomographic (CT) scans are done per year in the United States, a threefold increase since 1993.1 Abdominal CTs will detect liver metastases, and metastatic disease is found in 30 % of patients with small bowel NETs and 64 % of those with pancreatic NETs.2 Primary pancreatic NETs are commonly seen on CT if they are greater than 1 cm in size and appropriate administration of intravenous contrast is given. Primary small bowel NETs are more subtle because they are frequently small and intramural. They may show up as thickening of the bowel wall or a mass, but more commonly ...